FDA approves talazoparib plus enzalutamide for HRR gene–mutated mCRPC
The approval is based on findings from the phase 3 TALAPRO-2 trial.
Talazoparib plus enzalutamide significantly delays progression in HRR gene–altered mCRPC
The benefit in radiographic progression-free survival extended across all subgroups of patients with HRR-deficient metastatic castration-resistant prostate cancer.
Study shows potential of using machine learning to help manage prostate cancer
The researchers combined machine learning and rule-based natural language processing to develop an algorithm that leveraged electronic health records to identify patients with nmCRPC.
Novel PARP inhibitor shows promise across solid tumors, including prostate cancer
Initial data from the phase 1/2a modular PETRA trial showed that the next-generation highly selective PARP1 inhibitor AZD5305 had comparable safety and promising clinical activity compared with first-generation PARP inhibitors.
Lenvatinib/pembrolizumab shows efficacy and safety in East Asian patients with advanced renal cell carcinoma
5-year data sustain nivolumab/ipilimumab survival benefit in kidney cancer
The dual immunotherapy regimen maintained a survival benefit over single-agent sunitinib in patients with advanced renal cell carcinoma.
2 Clarke Drive Cranbury, NJ 08512